Strictly speaking, this relates to HIV but it also applies the Hepatitis C. Undetectable = Untransmissable Get tested, get treated, get cured! https://ashm.org.au/HIV/UequalsU/
Author Archives: Dr James
Blogs
Great News For Australian Patients – MAVIRET® (glecaprevir/pibrentasvir) PBS listed on 1 August 2018
26
Jul
Jul
News Flash MAVIRET® (glecaprevir/pibrentasvir) was listed on the PBS in Australia today. AbbVie is pleased to announce that MAVIRET is to be listed on the PBS on 1 August 2018 for the treatment of chronic hepatitis C virus (HCV) infection in adults. MAVIRET is a new 8 week pangenotypic treatment for treatment-naïve non-cirrhotic HCV adult […]
24
Jul
Jul
Most of the messaging to people about Hepatitis C is boring with as much cut through as a blunt knife through a block of titanium. If you were born between A and B, if this, if that, etc. It’s time to change the paradigm and speak to the simple reason for getting tested which is […]
08
Jul
Jul
The other day, on Facebook, I witnessed a patient, looking for advice, be given some very poor advice. Where poor = wrong and potentially lethal. I provided some accurate commentary which was deleted, leaving a whole lot of no doubt well-meaning, but nevertheless incorrect information. So the question to hand was “My father has sourced […]
07
Apr
Apr
They say (who are they anyway?) “If it seems to good to be true it probably is”. When it comes to generic Hepatitis C medication some people struggle with the idea that something like Harvoni® with a list price of $94,000 USD could be manufactured for under $1000 USD. Surely if the original costs $94,000 […]
13
Mar
Mar
So you’ve made it! SVR at last. What now? Here is a slideset from Clinical Care Options where Ira M. Jacobson, MD, and Paul Y. Kwo, MD, review optimal management of patients with HCV who have achieved SVR, including recommendations for HCV RNA and HCC monitoring. These doctors are world leading experts so you’re drinking from the source… Management_of_Patients_With_HCV_Who_Have_Achieved_SVR_1.pdf Management_of_Patients_With_HCV_Who_Have_Achieved_SVR_1.pptx
09
Mar
Mar
With HIV we observered that if we use 1 drug resistance develops rapidly, with 2 drugs it is slower, and with 3 drugs it virtually never happens, so it does not come as any great surprise that combining an NS3/4A drug with an NS5A drug and and NS5B drug works well. We have previously seen […]
12
Jan
Jan
Highlights Ravidasvir is a new NS5A inhibitor for HCV. Sofosbuvir + Ravidasvir with or without RBV has achieved very high SVR rates. Results are comparable for both patients with and without cirrhosis. Serious adverse events were noticed in very few treated patients. Background & Aims Although treatment of hepatitis C virus (HCV) and HCV-genotype-4 (GT4) has become […]
01
Jan
Jan
A quick note on how to take your DAA medication. Read the package insert and follow the instructions with respect to with (or without) food. For example, for Vosevii Administration with food enhances the oral bioavailability of sofosbuvir, velpatasvir, and voxilaprevir. Relative to fasting conditions, mean sofosbuvir systemic exposure (AUC) increased by 64% to 144%, […]
19
Dec
Dec
Any SVR rate <100% means a small number of people will not attain SVR. A 95% SVR means for every 20 people on generic treatment 1 patient will relapse. Back in early 2016 I came across an excellent article from Dr Jordan Feldwas kind enough to allow it to be reprinted here. It is a great […]